Ljubljana, 28 February (STA) - Salus, a wholesale supplier of medicines and other pharmaceutical products, generated EUR 253.15m in sales revenues last year or 8.79% more than in 2017. Operating profit was up by 12.81% to EUR 4.99m, while net profit increased by 11.38% to EUR 4.29m.
The growth of the group's revenue was higher than the average for the entire Slovenian pharmaceutical product market (6.68%), according to Salus's unaudited report for 2018 published on Thursday.
The largest company in the group, Salus Veletrgovina, generated EUR 250.88m in net sales revenue, up 8.43% year-on-year. Operating profit was up by 21.75% to EUR 5.13m, and net profit increased by 20.73% to EUR 4.47m.
The core company Salus increased its operating loss in 2018 to just under EUR 650,000, compared to EUR 240,000 in the year before.
Salus said that the poorer result was mainly connected to the costs of the acquisition Sanolabor, a company supplying and distributing medical devices and pharmaceutical products, at the end of last year.